Uno studio per valutare gli eventi avversi, l'efficacia e la dose ottimale di Telisotuzumab Adizutecan per via endovenosa (IV) in combinazione con Budigalimab IV in partecipanti adulti con NSCLC non squamoso avanzato o metastatico senza precedente trattamento per la malattia avanzata e senza alterazioni genomiche attuabili
Uno studio multi-coorte di fase 1b/2 in aperto per valutare la sicurezza, l'efficacia e la dose ottimale di telisotuzumab adizutecan in combinazione con budigalimab nel NSCLC non squamoso avanzato o metastatico senza trattamento precedente per la malattia avanzata e senza alterazioni genomiche attuabili
Non small cell lung carcinoma (NSCLC) is the most frequently occurring histologic subtype of lung cancer and is the leading cause of cancer-related deaths worldwide. The purpose of this study is to assess adverse events and change in disease activity when Telisotuzumab Adizutecan (ABBV-400) is given in combination with a programmed cell death receptor 1 (PD1) immune checkpoint inhibitor to adult participants to treat NSCLC.
Telisotuzumab Adizutecan (ABBV-400) and budigalimab are investigational drugs being developed for the treatment of NSCLC. This study will be divided into two stages, with the first stage treating participants with several doses of telisotuzumab adizutecan in combination with budigalimab within the dose escalation regimen until the dose reached is tolerable and expected to be efficacious. In Stage 2 there will be 3 treatment groups. Two groups will receive pembrolizumab with different optimized doses of telisotuzumab adizutecan (to allow for the best dose to be studied in the future). One group will receive the standard of care (SOC) - pembrolizumab, pemetrexed, and investigator's choice of carboplatin or cisplatin, followed by pembrolizumab and pemetrexed. Approximately 252 adult participants with NSCLC will be enrolled in the study in 132 sites worldwide.
In the dose escalation stage participants will be treated with increasing intravenous (IV) doses of Telisotuzumab Adizutecan in combination with budigalimab until the dose of Telisotuzumab Adizutecan reached is tolerable and expected to be efficacious. In the dose optimization stage participants will be receive IV optimized doses of Telisotuzumab Adizutecan in combination with IV pembrolizumab, or IV SOC - pembrolizumab, pemetrexed, and investigator's choice of carboplatin or cisplatin, followed by pembrolizumab and pemetrexed. The study will run for a duration of approximately 33 months.
There may be higher treatment burden for participants in this trial compared to their standard of care. Participants will attend regular visits during the study at an approved institution (hospital or clinic). The effect of the treatment will be frequently checked by medical assessments, blood tests, questionnaires and side effects.
Panoramica dello studio
Stato
Stato
Condizioni
Condizioni
Intervento / Trattamento
Intervento / Trattamento
Tipo di studio
Tipo di studio
Iscrizione (Stimato)
Iscrizione
Fase
Fase
- Fase 2
- Fase 1
Contatti e Sedi
Contatto studio
Contatto studio
- Nome: ABBVIE CALL CENTER
- Numero di telefono: 844-663-3742
- Email: abbvieclinicaltrials@abbvie.com
Luoghi di studio
-
-
-
Buenos Aires, Argentina, 1426
- Reclutamento
- Centro Oncologico Korben /ID# 281460
-
Buenos Aires, Argentina, 1426
- Reclutamento
- Fundacion Respirar /ID# 281039
-
-
Buenos Aires
-
Mar del Plata, Buenos Aires, Argentina, 7600
- Reclutamento
- Clinca Colon /ID# 281465
-
-
Buenos Aires F.D.
-
Ciudad Autonoma de Buenos Aire, Buenos Aires F.D., Argentina, 1426
- Reclutamento
- Instituto Alexander Fleming /ID# 282704
-
-
-
-
New South Wales
-
Blacktown, New South Wales, Australia, 2148
- Reclutamento
- Blacktown Hospital /ID# 281588
-
-
Queensland
-
Townsville, Queensland, Australia, 4814
- Reclutamento
- Townsville University Hospital /ID# 281498
-
-
South Australia
-
Elizabeth Vale, South Australia, Australia, 5112
- Reclutamento
- Lyell Mcewin Hospital /ID# 281860
-
-
Victoria
-
Frankston, Victoria, Australia, 3199
- Reclutamento
- Peninsula University Hospital /ID# 281824
-
-
-
-
-
Liège, Belgio, 4000
- Reclutamento
- Groupe Sante CHC - Clinique du MontLegia /ID# 271760
-
-
Limburg
-
Hasselt, Limburg, Belgio, 3500
- Reclutamento
- Jessa Ziekenhuis - Campus Virga Jesse /ID# 268573
-
-
Oost-Vlaanderen
-
Sint-Niklaas, Oost-Vlaanderen, Belgio, 9100
- Reclutamento
- Vitaz /Id# 280187
-
-
West-Vlaanderen
-
Roeselare, West-Vlaanderen, Belgio, 8800
- Reclutamento
- AZ-Delta. /ID# 272433
-
-
-
-
Region Metropolitana Santiago
-
Santiago, Region Metropolitana Santiago, Chile, 8330032
- Reclutamento
- Pontificia Universidad Catolica De Chile /ID# 281594
-
Vitacura, Region Metropolitana Santiago, Chile, 7650027
- Reclutamento
- Oncored /Id# 281108
-
-
Santiago Metropolitan
-
Santiago, Santiago Metropolitan, Chile, 6900941
- Reclutamento
- Fundacion Arturo Lopez Perez /ID# 281211
-
Santiago, Santiago Metropolitan, Chile, 7500713
- Reclutamento
- Orlandi Oncologia /ID# 281132
-
-
-
-
Beijing Municipality
-
Beijing, Beijing Municipality, Cina, 100021
- Reclutamento
- Cancer Hospital - Chinese Academy of Medical Sciences /ID# 269715
-
-
Fujian
-
Fuzhou, Fujian, Cina, 350014
- Reclutamento
- Fujian Province Cancer Hospital /ID# 269150
-
-
Guangxi
-
Liuzhou, Guangxi, Cina, 545006
- Reclutamento
- Liuzhou People's hospital /ID# 269667
-
-
Henan
-
Zhengzhou, Henan, Cina, 450008
- Reclutamento
- Henan Cancer Hospital /ID# 269668
-
-
Hubei
-
Wuhan, Hubei, Cina, 430022
- Reclutamento
- Union Hospital - Tongji Medical College /ID# 272286
-
-
Hunan
-
Changsha, Hunan, Cina, 410013
- Reclutamento
- Hunan Province Cancer Hospital /ID# 269679
-
-
Jiangsu
-
Nanjing, Jiangsu, Cina, 210008
- Reclutamento
- Nanjing Drum Tower Hospital /ID# 269762
-
-
Jiangxi
-
Nanchang, Jiangxi, Cina, 330209
- Reclutamento
- The First Affiliated Hospital of Nanchang University - Xianghu Campus /ID# 269190
-
-
Shaanxi
-
Xi'an, Shaanxi, Cina, 710061
- Reclutamento
- The First Affiliated Hospital of Xi'an Jiaotong University /ID# 271904
-
-
Shanghai Municipality
-
Shanghai, Shanghai Municipality, Cina, 200030
- Reclutamento
- Shanghai Chest Hospital /ID# 269155
-
Shanghai, Shanghai Municipality, Cina, 200433
- Reclutamento
- Shanghai Pulmonary Hospital /ID# 276397
-
-
Shanxi
-
Taiyuan, Shanxi, Cina, 030001
- Reclutamento
- First Affiliated Hospital of Shanxi Medical University /ID# 276482
-
-
Sichuan
-
Chengdu, Sichuan, Cina, 610041
- Reclutamento
- West China Hospital of Sichuan University /ID# 270244
-
Chengdu, Sichuan, Cina, 610041
- Reclutamento
- Sichuan Province Cancer Hospital /ID# 269712
-
-
Yunnan
-
Kunming, Yunnan, Cina, 650106
- Reclutamento
- Yunnan Province Cancer Hospital /ID# 272331
-
-
-
-
Gironde
-
Bordeaux, Gironde, Francia, 33000
- Reclutamento
- Institut Bergonie /ID# 258377
-
-
Loire-Atlantique
-
Saint-Herblain, Loire-Atlantique, Francia, 44800
- Reclutamento
- CHU Nantes - Hopital Laennec /ID# 268475
-
Saint-Herblain, Loire-Atlantique, Francia, 44805
- Reclutamento
- Institut de Cancerologie de l'Ouest Rene Gauducheau /ID# 268484
-
-
Occitanie
-
Montpellier, Occitanie, Francia, 34070
- Reclutamento
- Centre De Cancerologie Du Grand Montpellier /ID# 273724
-
-
Provence-Alpes-Côte d'Azur Region
-
Nice, Provence-Alpes-Côte d'Azur Region, Francia, 06189
- Reclutamento
- Centre Antoine-Lacassagne /ID# 268486
-
-
Val-de-Marne
-
Villejuif, Val-de-Marne, Francia, 94805
- Reclutamento
- Institut Gustave Roussy /ID# 258373
-
-
Île-de-France Region
-
Paris, Île-de-France Region, Francia, 75248
- Reclutamento
- Institut Curie /ID# 271395
-
-
-
-
Baden-Wurttemberg
-
Freiburg im Breisgau, Baden-Wurttemberg, Germania, 79106
- Reclutamento
- Universitaetsklinikum Freiburg /ID# 268473
-
Heilbronn, Baden-Wurttemberg, Germania, 74078
- Reclutamento
- Slk-Kliniken Heilbronn /ID# 269621
-
-
Bavaria
-
Augsburg, Bavaria, Germania, 86150
- Reclutamento
- Hamatologie-Onkologie im Zentrum MVZ GmbH /ID# 273043
-
Würzburg, Bavaria, Germania, 97080
- Reclutamento
- Universitaetsklinikum Wuerzburg /ID# 275445
-
-
Hesse
-
Frankfurt am Main, Hesse, Germania, 60590
- Reclutamento
- Universitaetsklinikum Frankfurt /ID# 268721
-
-
North Rhine-Westphalia
-
Cologne, North Rhine-Westphalia, Germania, 50937
- Reclutamento
- Universitaetsklinikum Koeln /ID# 268489
-
Hemer, North Rhine-Westphalia, Germania, 58675
- Reclutamento
- Lungenklinik Hemer /ID# 269779
-
-
Schleswig-Holstein
-
Oldenburg in Holstein, Schleswig-Holstein, Germania, 23758
- Reclutamento
- ohO Research GmbH /ID# 273060
-
-
Thuringia
-
Jena, Thuringia, Germania, 07747
- Reclutamento
- Universitatsklinikum Jena /ID# 269700
-
-
-
-
-
Nagasaki, Giappone, 852-8501
- Reclutamento
- Nagasaki University Hospital /ID# 273310
-
-
Aichi-ken
-
Nagoya, Aichi-ken, Giappone, 460-0001
- Reclutamento
- NHO Nagoya Medical Center /ID# 272515
-
Nagoya, Aichi-ken, Giappone, 464-8681
- Reclutamento
- Aichi Cancer Center /ID# 271978
-
-
Aomori
-
Hirosaki, Aomori, Giappone, 036-8563
- Reclutamento
- Hirosaki University Hospital /ID# 274410
-
-
Kanagawa
-
Yokohama, Kanagawa, Giappone, 221-0855
- Reclutamento
- Yokohama Municipal Citizen's Hospital /ID# 271979
-
-
Kyoto
-
Kyoto, Kyoto, Giappone, 606-8507
- Reclutamento
- Kyoto University Hospital /ID# 272312
-
-
Niigata
-
Niigata, Niigata, Giappone, 951-8520
- Reclutamento
- Niigata University Medical and Dental Hospital /ID# 274448
-
-
Osaka
-
Takatsuki, Osaka, Giappone, 569-8686
- Reclutamento
- Osaka Medical And Pharmaceutical University Hospital /ID# 273309
-
-
Tokyo
-
Chuo-Ku, Tokyo, Giappone, 104-0045
- Reclutamento
- National Cancer Center Hospital /ID# 273192
-
Koto-ku, Tokyo, Giappone, 135-8550
- Reclutamento
- The Cancer Institute Hospital Of Japanese Foundation for Cancer Research /ID# 271989
-
-
-
-
-
Bologna, Italia, 40138
- Reclutamento
- IRCCS AOU di Bologna Policlinico Sant Orsola Malpighi /ID# 268675
-
-
Forlì-Cesena
-
Meldola, Forlì-Cesena, Italia, 47014
- Reclutamento
- Istituto Romagnolo per lo Studio dei Tumori Dino Amadori IRST - IRCCS /ID# 268684
-
-
Milano
-
Milan, Milano, Italia, 20121
- Reclutamento
- Istituto Europeo Di Oncologia /Id# 268670
-
-
Roma
-
Rome, Roma, Italia, 00144
- Reclutamento
- IRCCS Istituti Fisioterapici Ospitalieri-Istituto Nazionale Tumori Regina Elena /ID# 268626
-
Rome, Roma, Italia, 00184
- Reclutamento
- Azienda Ospedaliera Complesso Ospedaliero San Giovanni-Addolorata /ID# 273438
-
-
The Marches
-
Ancona, The Marches, Italia, 60126
- Reclutamento
- Azienda Ospedaliero Universitaria delle Marche /ID# 268667
-
-
Torino
-
Orbassano, Torino, Italia, 10043
- Reclutamento
- Azienda Ospedaliero Universitaria San Luigi Gonzaga /ID# 268641
-
-
-
-
Lublin Voivodeship
-
Lublin, Lublin Voivodeship, Polonia, 20-090
- Reclutamento
- Uniwersytecki Szpital Kliniczny Nr 4 w Lublinie /ID# 273170
-
-
Podlaskie Voivodeship
-
Bialystok, Podlaskie Voivodeship, Polonia, 15-540
- Reclutamento
- Uniwersytecki Szpital Kliniczny w Bialymstoku /ID# 276848
-
-
Pomeranian Voivodeship
-
Gdansk, Pomeranian Voivodeship, Polonia, 80-214
- Reclutamento
- Uniwersyteckie Centrum Kliniczne /ID# 272418
-
-
Świętokrzyskie Voivodeship
-
Kielce, Świętokrzyskie Voivodeship, Polonia, 25-734
- Reclutamento
- Swietokrzyskie Centrum Onkologii Samodzielny Publiczny Zaklad Opieki Zdrowotnej /ID# 274549
-
-
-
-
-
Rio Piedras, Porto Rico, 00935
- Reclutamento
- Pan American Center for Oncology Trials - Rio Piedras /ID# 268827
-
-
-
-
-
Cardiff, Regno Unito, CF14 2TL
- Reclutamento
- Velindre Cancer Centre /ID# 271840
-
-
Leicestershire
-
Leicester, Leicestershire, Regno Unito, LE1 5WW
- Reclutamento
- University Hospitals of Leicester NHS Trust /ID# 276035
-
-
-
-
-
Bucharest, Romania, 013975
- Reclutamento
- MNT Healthcare Europe SRL /ID# 269075
-
Bucharest, Romania, 030171
- Reclutamento
- Spitalul Clinic Coltea /ID# 268726
-
Sibiu, Romania, 550253
- Reclutamento
- Clinica MedLife Polisano Sibiu /ID# 269078
-
-
Cluj
-
Cluj-Napoca, Cluj, Romania, 400080
- Reclutamento
- S.C. Radiotherapy Center Cluj SRL /ID# 268729
-
Cluj-Napoca, Cluj, Romania, 400015
- Reclutamento
- Institutul Oncologic Prof Dr Ion Chiricuta Cluj Napoca /ID# 273125
-
Cluj-Napoca, Cluj, Romania, 400015
- Reclutamento
- Institutul Oncologic Prof Dr Ion Chiricuta Cluj Napoca /ID# 268725
-
-
-
-
-
A Coruña, Spagna, 15006
- Reclutamento
- Complejo Hospitalario Universitario A Coruna /ID# 271456
-
Alicante, Spagna, 03010
- Reclutamento
- Hospital General Universitario de Alicante /ID# 271316
-
Barcelona, Spagna, 08036
- Reclutamento
- Hospital Clinic de Barcelona /ID# 271452
-
Barcelona, Spagna, 08041
- Reclutamento
- Hospital Santa Creu i Sant Pau /ID# 271311
-
Barcelona, Spagna, 08003
- Reclutamento
- Hospital del Mar /ID# 271310
-
Málaga, Spagna, 29010
- Reclutamento
- Hospital Universitario Virgen de la Victoria /ID# 271312
-
-
Cantabria
-
Santander, Cantabria, Spagna, 39008
- Reclutamento
- Hospital Universitario Marques de Valdecilla /ID# 271314
-
-
Sevilla
-
Seville, Sevilla, Spagna, 41009
- Reclutamento
- Hospital Universitario Virgen Macarena /ID# 271447
-
-
-
-
Arizona
-
Phoenix, Arizona, Stati Uniti, 85054
- Attivo, non reclutante
- Mayo Clinic Hospital - Phoenix /ID# 272971
-
-
California
-
Fullerton, California, Stati Uniti, 92835
- Reclutamento
- Providence - St. Jude Medical Center /ID# 271414
-
Oxnard, California, Stati Uniti, 93030
- Reclutamento
- FOMAT Medical Research - Clinica mi Salud by Focil Med /ID# 274450
-
Santa Monica, California, Stati Uniti, 90404
- Reclutamento
- UCLA - Santa Monica /ID# 271690
-
-
Colorado
-
Aurora, Colorado, Stati Uniti, 80045
- Reclutamento
- University Of Colorado - Anschutz Medical Campus /ID# 269069
-
Lone Tree, Colorado, Stati Uniti, 80124
- Reclutamento
- Rocky Mountain Cancer Centers - Lone Tree /ID# 272603
-
-
Florida
-
Jacksonville, Florida, Stati Uniti, 32224
- Reclutamento
- Mayo Clinic Hospital Jacksonville /ID# 275073
-
Orange City, Florida, Stati Uniti, 32763
- Reclutamento
- Mid Florida Hematology And Oncology Center /ID# 273777
-
-
Illinois
-
Hinsdale, Illinois, Stati Uniti, 60521
- Reclutamento
- Hope And Healing Cancer Services /ID# 276223
-
Contatto:
- Site Coordinator
- Numero di telefono: 6305600121
-
-
Indiana
-
Fort Wayne, Indiana, Stati Uniti, 46845
- Reclutamento
- Parkview Comprehensive Cancer Center /ID# 271879
-
Indianapolis, Indiana, Stati Uniti, 46202
- Completato
- Community Health Network /ID# 273437
-
-
Kansas
-
Overland Park, Kansas, Stati Uniti, 66210
- Reclutamento
- Kansas City Cancer Center /ID# 273679
-
-
Massachusetts
-
Boston, Massachusetts, Stati Uniti, 02215
- Reclutamento
- Dana-Farber Cancer Institute /ID# 278417
-
-
Michigan
-
Detroit, Michigan, Stati Uniti, 48202
- Reclutamento
- Henry Ford Hospital - Detroit /ID# 271642
-
-
Minnesota
-
Duluth, Minnesota, Stati Uniti, 55805
- Reclutamento
- St. Luke'S /ID# 273344
-
Rochester, Minnesota, Stati Uniti, 55905
- Reclutamento
- Mayo Clinic-Rochester /ID# 274512
-
-
New Jersey
-
East Brunswick, New Jersey, Stati Uniti, 08816-4096
- Reclutamento
- Astera Cancer Care /ID# 271915
-
-
New York
-
Shirley, New York, Stati Uniti, 11967
- Reclutamento
- New York Cancer And Blood Specialists - Shirley /ID# 272547
-
-
Ohio
-
Cleveland, Ohio, Stati Uniti, 44106
- Completato
- University Hospitals Cleveland Medical Center /ID# 271726
-
Columbus, Ohio, Stati Uniti, 43219
- Reclutamento
- The Mark H Zangmeister Center /ID# 272502
-
-
Pennsylvania
-
Easton, Pennsylvania, Stati Uniti, 18045
- Reclutamento
- Spoknwrd Clinical Trials /ID# 273776
-
Contatto:
- Site Coordinator
- Numero di telefono: 610-813-2087
-
-
Texas
-
Houston, Texas, Stati Uniti, 77090
- Completato
- Millennium Physicians /ID# 271717
-
Lubbock, Texas, Stati Uniti, 79410-1121
- Reclutamento
- Joe Arrington Cancer Research /ID# 272776
-
-
Utah
-
Salt Lake City, Utah, Stati Uniti, 84112
- Reclutamento
- Huntsman Cancer Institute /ID# 271686
-
-
Virginia
-
Leesburg, Virginia, Stati Uniti, 20176
- Reclutamento
- Virgnia Cancer Specialists /ID# 269633
-
-
Washington
-
Olympia, Washington, Stati Uniti, 98506
- Reclutamento
- Vista Oncology - East Olympia /ID# 275438
-
Tacoma, Washington, Stati Uniti, 98405
- Reclutamento
- Northwest Medical Specialties Tacoma /ID# 270469
-
-
-
-
-
Changhua, Taiwan, 500
- Reclutamento
- Changhua Christian Hospital /ID# 280139
-
Chiayi City, Taiwan, 62247
- Reclutamento
- Dalin Tzu Chi Hospital, Buddhist Tzu Chi Medical Foundation /ID# 268789
-
Kaohsiung City, Taiwan, 807
- Reclutamento
- Kaohsiung Medical University Chung-Ho Memorial Hospital /ID# 268139
-
Kaohsiung City, Taiwan, 833
- Reclutamento
- Kaohsiung Chang Gung Memorial Hospital /ID# 268138
-
Taipei, Taiwan, 114
- Reclutamento
- Tri-Service General Hospital /ID# 269211
-
Taipei, Taiwan, 106
- Reclutamento
- National Taiwan University Cancer Center (Ntucc) /ID# 271586
-
Taipei, Taiwan, 112
- Reclutamento
- Taipei Veterans General Hospital /ID# 268787
-
Taoyuan City, Taiwan, 333
- Reclutamento
- Linkou Chang Gung Memorial Hospital /ID# 268137
-
-
-
-
-
Adana, Turchia (Türkiye), 01140
- Reclutamento
- Adana Medical Park Seyhan Hastanesi /ID# 272875
-
Ankara, Turchia (Türkiye), 06620
- Reclutamento
- Ankara Universitesi Tip Fakultesi Cebeci Hastanesi /ID# 272873
-
Ankara, Turchia (Türkiye), 06680
- Reclutamento
- Liv Hospital Ankara /ID# 272876
-
Ankara, Turchia (Türkiye), 06230
- Reclutamento
- Hacettepe Universitesi Tip Fakultesi /ID# 280631
-
Denizli, Turchia (Türkiye), 20070
- Reclutamento
- Pamukkale Universitesi /ID# 272893
-
Istanbul, Turchia (Türkiye), 34722
- Reclutamento
- Goztepe Prof. Dr. Suleyman Yalcin Sehir Hastanesi /ID# 280635
-
Konya, Turchia (Türkiye), 42080
- Reclutamento
- Necmettin Erbakan Universitesi Meram Tip Fakultesi - Eski Hastane /ID# 272882
-
Samsun, Turchia (Türkiye), 55139
- Reclutamento
- Ondokuz Mayis Universitesi /ID# 272899
-
Samsun, Turchia (Türkiye), 55200
- Reclutamento
- Samsun Medical Park Hastanesi /ID# 272880
-
-
Antalya
-
Ankara, Antalya, Turchia (Türkiye), 06010
- Reclutamento
- Gulhane Egitim ve Arastirma Hastanesi /ID# 280715
-
-
Sakarya
-
Adapazarı, Sakarya, Turchia (Türkiye), 54290
- Reclutamento
- Sakarya Egitim ve Arastirma Hastanesi /ID# 272878
-
-
Criteri di partecipazione
Criteri di ammissibilità
Criteri di ammissibilità
Età idonea allo studio
Accetta volontari sani
Sessi ammissibili allo studio
Descrizione
Inclusion Criteria:
- Must have histologically documented non-squamous (NSq) non small cell lung carcinoma (NSCLC) that is locally advanced or metastatic will be enrolled into the study.
- Must have measurable disease per response evaluation criteria in solid tumors (RECIST) v1.1.
- For Part 1, participants must have had no more than 1 systemic therapy for advanced disease including platinum-based chemotherapy or an immune checkpoint inhibitor (as monotherapy or in combination with chemotherapy), or appropriate targeted therapy for an actionable gene alteration, if applicable, for epidermal growth factor receptor (EGFR) wild-type (WT) NSq NSCLC.
- For Part 2, participants must have no prior systemic therapy for advanced disease, no known actionable genomic alteration.
- Must have documented programmed death ligand 1 (PD-L1) status.
- For Part 2, participant must have evaluable c-Met immunohistochemistry (IHC) result per central testing prior to randomization.
- Must have adequate organ function.
Exclusion Criteria:
- Known uncontrolled metastases to the central nervous system.
- History of interstitial lung disease (ILD) or pneumonitis that required treatment with systemic steroids, or any evidence of active ILD or pneumonitis on screening chest computed tomography (CT) scan.
Piano di studio
Come è strutturato lo studio?
Dettagli di progettazione
- Scopo principale: Trattamento
- Assegnazione: Randomizzato
- Modello interventistico: Assegnazione sequenziale
- Mascheramento: Nessuno (etichetta aperta)
Numero di armi
Armi e interventi
Gruppo di partecipanti / ArmGruppo di partecipanti / Arm |
Intervento / TrattamentoIntervento / Trattamento |
|---|---|
|
Sperimentale: Part 1: Telisotuzumab Adizutecan + Budigalimab
Participants will receive several doses of telisotuzumab adizutecan in combination with budigalimab, as part of the 33 month study duration. |
Intravenous (IV) Infusion
Altri nomi:
IV Infusion
Altri nomi:
|
|
Sperimentale: Part 2 Arm 1: Telisotuzumab Adizutecan + Pembrolizumab
Participants will receive telisotuzumab adizutecan dose A in combination with pembrolizumab, as part of the 33 month study duration. |
Intravenous (IV) Infusion
Altri nomi:
IV Injection IV Infusion |
|
Sperimentale: Part 2 Arm 2: Telisotuzumab Adizutecan + Pembrolizumab
Participants will receive telisotuzumab adizutecan dose B in combination with pembrolizumab, as part of the 33 month study duration. |
Intravenous (IV) Infusion
Altri nomi:
IV Injection IV Infusion |
|
Sperimentale: Part 2: Standard of Care
Participants will receive pembrolizumab, pemetrexed, and investigator's choice of carboplatin or cisplatin, followed by pembrolizumab and pemetrexed, as part of the 33 month study duration. |
IV Infusion IV Infusion IV Injection IV Infusion IV Infusion |
Cosa sta misurando lo studio?
Misure di risultato primarie
Misure di risultato primarie
Misura del risultato |
Misura Descrizione |
Lasso di tempo |
|---|---|---|
|
Part 1: Dose-Limiting Toxicities (DLT)s of Telisotuzumab Adizutecan
Lasso di tempo: Up to Approximately 84 Days
|
DLT events are defined as clinically significant adverse events or abnormal laboratory values assessed as unrelated to disease progression, underlying disease, intercurrent illness, or concomitant medications. |
Up to Approximately 84 Days
|
|
Part 2: Objective Response (OR) as Assessed by Blinded Independent Central Review (BICR)
Lasso di tempo: Up to Approximately 33 Months
|
OR is defined as confirmed complete response (CR) or confirmed partial response (PR) per BICR based on Response Evaluation Criteria in Solid Tumors (RECIST) v1.1. |
Up to Approximately 33 Months
|
|
Number of Participants with Adverse Events (AE)s
Lasso di tempo: Up to Approximately 33 Months
|
An adverse event is defined as any untoward medical occurrence in a participant or clinical investigation subject administered a pharmaceutical product and which does not necessarily have a causal relationship with this treatment. |
Up to Approximately 33 Months
|
Misure di risultato secondarie
Misure di risultato secondarie
Misura del risultato |
Misura Descrizione |
Lasso di tempo |
|---|---|---|
|
Part 1 and Part 2: PFS as Assessed by Investigator
Lasso di tempo: Up to Approximately 33 Months
|
PFS is defined as the time from the participant's randomization date to the first occurrence of radiographic progression per Investigator based on RECIST v1.1 or death from any cause, whichever occurs earlier. |
Up to Approximately 33 Months
|
|
Part 1 and Part 2: DOR as Assessed by Investigator
Lasso di tempo: Up to Approximately 33 Months
|
DOR is defined as the time from the first documented CR or PR per investigator to the first occurrence of radiographic progression per the investigator on RECIST v1.1 or death from any cause, whichever occurs first. DOR is defined for participants with confirmed CR/PR. |
Up to Approximately 33 Months
|
|
Part 1 and Part 2: DC as Assessed by Investigator
Lasso di tempo: Up to Approximately 33 Months
|
DC is defined as best overall response of confirmed CR or confirmed PR, or SD for at least 11 weeks following randomization date based on RECIST v1.1, as determined by the Investigator. |
Up to Approximately 33 Months
|
|
Part 1 and Part 2: Overall Survival (OS)
Lasso di tempo: Up to Approximately 33 Months
|
OS is defined as the time from participant's randomization date (Part 2) or first dose date of study treatment (Part 1) to the event of death from any cause. |
Up to Approximately 33 Months
|
|
Programmed Death Ligand 1 (PD-L1) and c-Met Subgroups: OR
Lasso di tempo: Up to Approximately 33 Months
|
OR is defined as confirmed CR or confirmed PR based on RECIST v1.1. |
Up to Approximately 33 Months
|
|
PD-L1 and c-Met Subgroups: PFS
Lasso di tempo: Up to Approximately 33 Months
|
PFS is defined as the time from the participant's randomization date to the first occurrence of radiographic progression based on RECIST v1.1 or death from any cause, whichever occurs earlier. |
Up to Approximately 33 Months
|
|
PD-L1 and c-Met Subgroups: OS
Lasso di tempo: Up to Approximately 33 Months
|
OS is defined as the time from participant's randomization date (Part 2) or first dose date of study treatment (Part 1) to the event of death from any cause. |
Up to Approximately 33 Months
|
|
PD-L1 and c-Met Subgroups: DOR
Lasso di tempo: Up to Approximately 33 Months
|
DOR is defined as the time from the first documented CR or PR to the first occurrence of radiographic progression per RECIST v1.1 or death from any cause, whichever occurs first. DOR is defined for participants with confirmed CR/PR. |
Up to Approximately 33 Months
|
|
PD-L1 and c-Met Subgroups: DC
Lasso di tempo: Up to Approximately 33 Months
|
DC is defined as best overall response of confirmed CR or confirmed PR, or SD for at least 12 weeks following randomization date based on RECIST v1.1. |
Up to Approximately 33 Months
|
Collaboratori e investigatori
Sponsor
Sponsor
Investigatori
Investigatori
- Direttore dello studio: ABBVIE INC., AbbVie
Studiare le date dei record
Studia le date principali
Inizio studio (Effettivo)
Inizio studio
Completamento primario (Stimato)
Completamento primario
Completamento dello studio (Stimato)
Completamento dello studio
Date di iscrizione allo studio
Primo inviato
Primo inviato
Primo inviato che soddisfa i criteri di controllo qualità
Primo inviato che soddisfa i criteri di controllo qualità
Primo Inserito (Effettivo)
Primo Inserito
Aggiornamenti dei record di studio
Ultimo aggiornamento pubblicato (Effettivo)
Ultimo aggiornamento pubblicato
Ultimo aggiornamento inviato che soddisfa i criteri QC
Ultimo aggiornamento inviato che soddisfa i criteri QC
Ultimo verificato
Ultimo verificato
Maggiori informazioni
Termini relativi a questo studio
Parole chiave
Termini MeSH pertinenti aggiuntivi
- Neoplasie per sede
- Neoplasie
- Malattie delle vie respiratorie
- Malattie polmonari
- Neoplasie delle vie respiratorie
- Neoplasie toraciche
- Neoplasie polmonari
- Carcinoma, broncogeno
- Neoplasie bronchiali
- Carcinoma, polmone non a piccole cellule
- Aminoacidi, peptidi e proteine
- Prodotti chimici organici
- Composti eterociclici
- Composti eterociclici, 2 anelli
- Composti eterociclici, anello fuso
- Prodotti chimici inorganici
- Composti di cloro
- Composti di azoto
- Complessi di coordinamento
- Guanina
- Ipossantine
- Purinoni
- Purine
- Glutammati
- Aminoacidi, acido
- Aminoacidi
- Aminoacidi, dicarbossilico
- Composti di platino
- Pemetrexed
- Carboplatino
- Cisplatino
- pembrolizumab
- Budigalimab
Altri numeri di identificazione dello studio
Altri numeri di identificazione dello studio
- M24-536
- 2024-514465-18 (Altro identificatore: EU CT)
- 2024-514465-18-00 (Ctis)
Piano per i dati dei singoli partecipanti (IPD)
Hai intenzione di condividere i dati dei singoli partecipanti (IPD)?
Descrizione del piano IPD
AbbVie is committed to responsible clinical trial data sharing. This includes access to anonymized, individual and trial-level data (analysis data sets), as well as other information.
Periodo di condivisione IPD
For details on when studies are available for sharing, visit https://vivli.org/ourmember/abbvie/
Criteri di accesso alla condivisione IPD
To learn more about the process, or to submit a request, visit the following link https://www.abbvieclinicaltrials.com/hcp/data-sharing/
Tipo di informazioni di supporto alla condivisione IPD
- STUDIO_PROTOCOLLO
- LINFA
Informazioni su farmaci e dispositivi, documenti di studio
Studia un prodotto farmaceutico regolamentato dalla FDA degli Stati Uniti
Studia un dispositivo regolamentato dalla FDA degli Stati Uniti
prodotto fabbricato ed esportato dagli Stati Uniti
Queste informazioni sono state recuperate direttamente dal sito web clinicaltrials.gov senza alcuna modifica. In caso di richieste di modifica, rimozione o aggiornamento dei dettagli dello studio, contattare register@clinicaltrials.gov. Non appena verrà implementata una modifica su clinicaltrials.gov, questa verrà aggiornata automaticamente anche sul nostro sito web .